« Antibody-Drug Conjugates Continue to Gain Momentum | Main | Is Cancer Research Focused on Too Few Targets? »

06/06/2012

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b0167671eae64970b

Listed below are links to weblogs that reference Reports on ASCO Consolidated:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

In addition to its ADC, T-DM1, Genentech is also awaiting an FDA green light on its new HER2 drug pertuzumab (Perjeta).
http://www.xconomy.com/san-francisco/2012/06/07/genentech-eagerly-awaits-fda-word-on-2nd-breast-cancer-drug/

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada